Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. Yesterday, Feb. 10, 2014, 89 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $310.00 to $48,325,837.35.
Highlighted Stocks Traded by Insiders:
Illumina (ILMN) - FREE Research Report Flatley Jay T who is Ceo at Illumina sold 5,000 shares at $152.23 on Feb. 10, 2014. Following this transaction, the Ceo owned 6,000 shares meaning that the stake was reduced by 45.45% with the 5,000-share transaction.
The shares most recently traded at $160.77, up $8.54, or 5.31% since the insider transaction. Historical insider transactions for Illumina go as follows:
- 4-Week # shares sold: 12,884
- 12-Week # shares sold: 17,884
- 24-Week # shares sold: 49,511
The average volume for Illumina has been 1.6 million shares per day over the past 30 days. Illumina has a market cap of $19.8 billion and is part of the health care sector and drugs industry. Shares are up 41.88% year-to-date as of the close of trading on Monday.
Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation and biological function in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. The company has a P/E ratio of 87.2. Currently there are 7 analysts that rate Illumina a buy, no analysts rate it a sell, and 10 rate it a hold.
Exclusive Offer: Get the latest Stock Analysis on ILMN - FREE TheStreet Quant Ratings rates Illumina as a
buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins, good cash flow from operations and increase in net income. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full
Illumina Ratings Report from
TheStreet Quant Ratings now.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
Maximus (MMS) - FREE Research Report Walker David N who is Cfo at Maximus sold 58,405 shares at $47.61 on Feb. 10, 2014. Following this transaction, the Cfo owned 17,189 shares meaning that the stake was reduced by 77.26% with the 58,405-share transaction.
The shares most recently traded at $47.62, up $0.01, or 0.02% since the insider transaction. Historical insider transactions for Maximus go as follows:
- 4-Week # shares sold: 4,302
- 12-Week # shares sold: 20,208
- 24-Week # shares sold: 59,803
The average volume for Maximus has been 439,000 shares per day over the past 30 days. Maximus has a market cap of $3.2 billion and is part of the services sector and diversified services industry. Shares are up 8.55% year-to-date as of the close of trading on Monday.
MAXIMUS, Inc. provides business process services to government health and human services agencies in the United States, Australia, Canada, the United Kingdom, and Saudi Arabia. The company operates in two segments, Health Services and Human Services. The stock currently has a dividend yield of 0.38%. The company has a P/E ratio of 25.5. Currently there are 5 analysts that rate Maximus a buy, no analysts rate it a sell, and none rate it a hold.
Exclusive Offer: Get the latest Stock Analysis on MMS - FREE TheStreet Quant Ratings rates Maximus as a
buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, compelling growth in net income and good cash flow from operations. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full
Maximus Ratings Report from
TheStreet Quant Ratings now.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
AmeriGas Partners (APU) - FREE Research Report Turner K Rick who is Director at AmeriGas Partners bought 2,500 shares at $41.43 on Feb. 10, 2014. Following this transaction, the Director owned 5,500 shares meaning that the stake was reduced by 83.33% with the 2,500-share transaction.
The shares most recently traded at $42.29, up $0.86, or 2.04% since the insider transaction. Historical insider transactions for AmeriGas Partners go as follows:
- 12-Week # shares bought: 250
- 24-Week # shares bought: 250
The average volume for AmeriGas Partners has been 378,700 shares per day over the past 30 days. AmeriGas Partners has a market cap of $3.9 billion and is part of the utilities sector and utilities industry. Shares are down 5.43% year-to-date as of the close of trading on Monday.
AmeriGas Partners, L.P. operates as a retail and wholesale distributor of propane gas, and related equipment and supplies in the United States. The stock currently has a dividend yield of 8.08%. The company has a P/E ratio of 17.7. Currently there are 2 analysts that rate AmeriGas Partners a buy, 2 analysts rate it a sell, and 4 rate it a hold.
Exclusive Offer: Get the latest Stock Analysis on APU - FREE TheStreet Quant Ratings rates AmeriGas Partners as a
buy. The company's strengths can be seen in multiple areas, such as its revenue growth, impressive record of earnings per share growth, compelling growth in net income and expanding profit margins. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full
AmeriGas Partners Ratings Report from
TheStreet Quant Ratings now.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
Energizer Holdings (ENR) - FREE Research Report Heinrich Daniel J who is Director at Energizer Holdings bought 530 shares at $94.94 on Feb. 10, 2014. Following this transaction, the Director owned 2,030 shares meaning that the stake was reduced by 35.33% with the 530-share transaction.
The shares most recently traded at $95.46, up $0.52, or 0.54% since the insider transaction. Historical insider transactions for Energizer Holdings go as follows:
- 4-Week # shares sold: 3,852
- 12-Week # shares sold: 8,292
- 24-Week # shares sold: 26,561
The average volume for Energizer Holdings has been 574,900 shares per day over the past 30 days. Energizer Holdings has a market cap of $5.9 billion and is part of the consumer goods sector and consumer non-durables industry. Shares are down 11.03% year-to-date as of the close of trading on Monday.
Energizer Holdings, Inc. manufactures and sells primary batteries, portable lighting, and personal care products worldwide. It offers household and specialty batteries, including carbon zinc, alkaline, rechargeable, and lithium batteries. The stock currently has a dividend yield of 2.11%. The company has a P/E ratio of 15.5. Currently there are 7 analysts that rate Energizer Holdings a buy, no analysts rate it a sell, and 3 rate it a hold.
Exclusive Offer: Get the latest Stock Analysis on ENR - FREE TheStreet Quant Ratings rates Energizer Holdings as a
buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, increase in stock price during the past year and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full
Energizer Holdings Ratings Report from
TheStreet Quant Ratings now.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
Parexel International Corporation (PRXL) - FREE Research Report Von Rickenbach Josef H who is Chairman & CEO at Parexel International Corporation sold 50,000 shares at $49.70 on Feb. 10, 2014. Following this transaction, the Chairman & CEO owned 612,641 shares meaning that the stake was reduced by 7.55% with the 50,000-share transaction.
Holdener Eduard E. who is Director at Parexel International Corporation sold 6,000 shares at $49.62 on Feb. 10, 2014. Following this transaction, the Director owned 13,289 shares meaning that the stake was reduced by 31.11% with the 6,000-share transaction.
The shares most recently traded at $49.63, up $0.01, or 0.02% since the insider transaction. Historical insider transactions for Parexel International Corporation go as follows:
- 4-Week # shares bought: 5,000
- 4-Week # shares sold: 23,529
- 12-Week # shares bought: 5,000
- 12-Week # shares sold: 23,529
- 24-Week # shares bought: 5,000
- 24-Week # shares sold: 35,529
The average volume for Parexel International Corporation has been 674,300 shares per day over the past 30 days. Parexel International Corporation has a market cap of $2.8 billion and is part of the health care sector and health services industry. Shares are up 10.07% year-to-date as of the close of trading on Monday.
PAREXEL International Corporation, a biopharmaceutical services company, provides clinical research, medical communications, consulting, commercialization, and advanced technology products and services to the pharmaceutical, biotechnology, and medical device industries worldwide. The company has a P/E ratio of 25.4. Currently there are 5 analysts that rate Parexel International Corporation a buy, 1 analyst rates it a sell, and 5 rate it a hold.
Exclusive Offer: Get the latest Stock Analysis on PRXL - FREE TheStreet Quant Ratings rates Parexel International Corporation as a
buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and good cash flow from operations. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full
Parexel International Corporation Ratings Report from
TheStreet Quant Ratings now.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. Data for this article provided by
Zacks Investment Research
